Psychopharmacology

Why, for some, psychotherapy might be a better treatment for depression than drugs

Retrieved on: 
星期日, 六月 2, 2024
Insomnia, GP, Patient, Prescription, Hope, Headache, Risk, Psychopharmacology, Nausea, Psychotherapy, Nervous, Depression, Anxiety, Dizziness, Lethargy, Health, Mental health, Optimism, Weakness, Argyreia nervosa, Hallucination, Research, Irritability, Sickness, Fatigue, Somnolence, Agitation, Suicide, Psilocybin, Vertigo, Selective serotonin reuptake inhibitor, Pharmaceutical industry
Key Points: 

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, MDD, Society, Social anxiety disorder, Psychopharmacology, Publication, SAD, Psychiatry, DSM-IV codes, Conference

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2 development for the treatment of major depressive disorder (MDD), at the American Society of Clinical Psychopharmacology Conference in Miami Beach, Florida from May 28 to 31, 2024.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2 development for the treatment of major depressive disorder (MDD), at the American Society of Clinical Psychopharmacology Conference in Miami Beach, Florida from May 28 to 31, 2024.
  • The posters will be available on the Publications page of Vistagen’s website on Monday, June 3, 2024.

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
星期二, 五月 14, 2024
Mental Health, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, CIAS, PET, Partnership, Patient, PDE4, Human, EEG, MDD, Central nervous system disease, Depression, Overalls, Safety, NMDA, Dopamine, Neuroscience, CNS, DSM-IV codes, Brain, Society, Psychopharmacology, Research, Schizophrenia, Anhedonia, Cognition, Histamine, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by a memory-based cognitive biomarker.
  • Enrollment is ongoing and the Company expects to report topline data in the second half of 2024.
  • Net Loss: The Company incurred a net loss of $13.4 million for the quarter ended March 31, 2024, as compared to $7.3 million for the quarter ended March 31, 2023.

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

Retrieved on: 
星期四, 一月 18, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Psychopharmacology, ACAD, Development, Psychiatry, Patient, Research, Forest Laboratories, Teva Pharmaceuticals, Humour, Friends, Rett syndrome, University, Medicine, Public health, Drug development, Caregiver, Johnson & Johnson, Birmingham School of Law, Private sector, Pharmaceutical industry

(Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H.

Key Points: 
  • (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H.
  • “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years.
  • Serge transitioned to the private sector as a medical officer at UCB Pharma and quickly rose through the organization to Vice President of U.S. Clinical Development.
  • He went on to hold leadership positions in research and development at Johnson & Johnson, Neurogen Pharmaceuticals, Forest Laboratories, Teva Pharmaceuticals, and Alkermes.

Sheppard Pratt Announces Dr. Matthew W. Johnson as Senior Researcher for the Center of Excellence for Psilocybin Research and Treatment

Retrieved on: 
星期四, 一月 18, 2024
Psilocybin, Psychopharmacology, University, Therapy, Research, Tic disorder, MD, PTSD, DSM-IV codes, Psychotherapy, Post-traumatic stress disorder, American Psychological Association, Science, History, Pharmacology, Johns Hopkins, Economics, Psychiatry, University of Oregon, Argyreia nervosa, Experimental psychology, OCD, Safety, Publishing, Eastern Oregon University, Doctor of Philosophy, Biological psychiatry, Treatment, International Society, Depression, Pharmaceutical industry

The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.

Key Points: 
  • The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.
  • In his role as senior researcher, Dr. Johnson will join Sheppard Pratt in their efforts to integrate biological psychiatry with psychotherapy.
  • Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment brings together evidence-based innovation and the development of psychedelic therapeutics on a large scale.
  • To learn more about Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics and Center of Excellence for Psilocybin Research and Treatment, visit www.sheppardpratt.org/the-institute-for-advanced-diagnostics-and-therape... .

Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed

Retrieved on: 
星期四, 十二月 14, 2023
Veteran, Spectrum, Journal of Affective Disorders, Journal of Psychopharmacology, MAPS, Research, Psychopharmacology, Ketamine, JAMA Oncology, DSM-IV codes, Education, Palliative care, Cancer, University, Sunstone, Post-traumatic stress disorder, Patient, PAT, Journal, Johns Hopkins, Pharmaceutical industry

Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.

Key Points: 
  • Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.
  • Manish Agrawal MD, CEO and Co-founder of Sunstone Therapies, said: “The development of psychedelic-assisted therapy, and the understanding of the impact it can have, has progressed so much over the last three years.
  • We are using the extensive experience we have gained in delivering these therapies, through sponsored clinical trials and our own investigator-initiated studies, to develop a patient-centric delivery model that can be scaled responsibly in the real world.
  • Delivery of psychedelic therapies is complex, requiring significant capabilities and experience in logistics, infrastructure and training, as well as clinical care.

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

Retrieved on: 
星期四, 十二月 7, 2023
Sleep medicine, Psychiatry, Attention deficit hyperactivity disorder, Obstructive sleep apnea, Eastern Time Zone, Division, Binge eating disorder, TAAR1, Psychopharmacology, BED, SHARP, Medical school, DSM-IV codes, MD, Doctor of Philosophy, Research, Therapy, University, HOPE, Associate, EDS, CNS, Narcolepsy, OSA, Webcast, Central nervous system, MDD, Patient, ADHD, Harvard Medical School, Dopamine, SWD

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • Expert thought leaders presenting at the event include:
    Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health.
  • A replay of the webcast will be available for approximately 30 days following the live event.

AHN Appoints Ewurama Sackey, MD, as Medical Director of Maternal-Infant Mental Health

Retrieved on: 
星期二, 十二月 19, 2023
Psychiatry, Lead, Hospital, UCLA, Trauma, Pregnancy, Paul Sackey, Multimedia, Mental health, Adolescence, Caregiver, WBH, Psychopathology, Parent, Western Pennsylvania Hospital, MD, Doctor of Philosophy, AHN, Allegheny Health Network, Psychopharmacology, University, Patient, Anxiety, Nursing

PITTSBURGH, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.

Key Points: 
  • Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.
  • PITTSBURGH, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.
  • "Joining a health care organization that is nationally recognized for its parent-infant mental health program is incredibly invigorating," said Dr. Sackey.
  • The Alexis Joy D'Achille Center for Perinatal Mental Health at West Penn Hospital serves as the flagship location for the Women's Behavioral Health program.

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
星期二, 十一月 14, 2023
Sale, Acquisition, Safety, Pivotal, EGX, DMT, Entrepreneurship, Aes, Plasma, MDMA, Investment, Exercise, CIAS, Administration, Patient, QT, Research, Cognition, American College, G&A, Pharmacology, OTF, Permeability, Drug discovery, IB, TRD, PTSD, OUD, R, Neuroscience, Research and development, Mental health, AI, Poster, Taste, Pharmaceutical industry, Bank, Medicinal plants, Rare-earth element, Vaccine, Medical device, Psychopharmacology, Anorexia nervosa, Ibogaine

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.

Key Points: 
  • NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.
  • The on-going Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients with CIAS, with topline results expected in 2H 2024.
  • The poster will be presented at the American College of Neuropsychopharmacology (ACNP) annual meeting on Dec 5, 2023, 5:00 – 7:00 PM ET.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc.

Worried about psychedelic use? The Psychedelic Wellness and Healing Initiative of 2024 is the solution

Retrieved on: 
星期二, 十一月 21, 2023
Advocacy Group Opinion, Cannabis, Public Policy, Government, Healthcare Reform, Alternative Medicine, Health, State, Local, Natural Resources, Public Safety, Psilocybin, Human, Depression, Safety, Post-traumatic stress disorder, University, Traumatic brain injury, Addiction, Psychotherapy, Patient, Research, Tic disorder, Psychopharmacology, Suicide, Anxiety, Weill Cornell Medicine, PTSD, Columbia University, News, Ecstasy, The Atlantic, Nightclub, Medical device, Pharmaceutical industry

Achieving psychedelic access has become Hodges’ mission, one now embodied in the Psychedelic Wellness & Healing Initiative headed for the 2024 ballot.

Key Points: